Next Article in Journal
Influence of the Metabolism on Myeloid Cell Functions in Cancers: Clinical Perspectives
Previous Article in Journal
Oxidative Stress in Human Pathology and Aging: Molecular Mechanisms and Perspectives
Previous Article in Special Issue
A Novel Megakaryocyte Subpopulation Poised to Exert the Function of HSC Niche as Possible Driver of Myelofibrosis
Review

How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation

1
Unit of Blood Diseases and Bone Marrow Transplantation, Cell Therapies and Hematology Research Program, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy
2
Hematology Division, Department of Oncology, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy
3
2nd Division of General Surgery, Department of Medical & Surgical Sciences, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy
4
Department of Radiology, ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy
5
CREA Laboratory (Centro di Ricerca Emato-Oncologica AIL), ASST Spedali Civili di Brescia, P.le Spedali Civili 1, 25123 Brescia, BS, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Marco Vitale and Elena Masselli
Cells 2022, 11(3), 553; https://doi.org/10.3390/cells11030553
Received: 25 December 2021 / Revised: 31 January 2022 / Accepted: 3 February 2022 / Published: 5 February 2022
Moving from indication to transplantation is a critical process in myelofibrosis. Most of guidelines specifically focus on either myelofibrosis disease or transplant procedure, and, currently, no distinct indication for the management of MF candidates to transplant is available. Nevertheless, this period of time is crucial for the transplant outcome because engraftment, non-relapse mortality, and relapse incidence are greatly dependent upon the pre-transplant management. Based on these premises, in this review, we will go through the path of identification of the MF patients suitable for a transplant, by using disease-specific prognostic scores, and the evaluation of eligibility for a transplant, based on performance, comorbidity, and other combined tools. Then, we will focus on the process of donor and conditioning regimens’ choice. The pre-transplant management of splenomegaly and constitutional symptoms, cytopenias, iron overload and transplant timing will be comprehensively discussed. The principal aim of this review is, therefore, to give a practical guidance for managing MF patients who are potential candidates for allo-HCT. View Full-Text
Keywords: myelofibrosis; allogeneic stem cell transplantation; bone marrow transplantation; ruxolitinib; splenectomy; JAK-inhibitors; iron overload; deferasirox myelofibrosis; allogeneic stem cell transplantation; bone marrow transplantation; ruxolitinib; splenectomy; JAK-inhibitors; iron overload; deferasirox
Show Figures

Figure 1

MDPI and ACS Style

Polverelli, N.; Farina, M.; D’Adda, M.; Damiani, E.; Grazioli, L.; Leoni, A.; Malagola, M.; Bernardi, S.; Russo, D. How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation. Cells 2022, 11, 553. https://doi.org/10.3390/cells11030553

AMA Style

Polverelli N, Farina M, D’Adda M, Damiani E, Grazioli L, Leoni A, Malagola M, Bernardi S, Russo D. How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation. Cells. 2022; 11(3):553. https://doi.org/10.3390/cells11030553

Chicago/Turabian Style

Polverelli, Nicola, Mirko Farina, Mariella D’Adda, Enrico Damiani, Luigi Grazioli, Alessandro Leoni, Michele Malagola, Simona Bernardi, and Domenico Russo. 2022. "How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation" Cells 11, no. 3: 553. https://doi.org/10.3390/cells11030553

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop